The influence of ageing on the development and management of rheumatoid arthritis

Nature Reviews Rheumatology

Volumn 9, Issue 10, 2013, Pages 604-613

  Boots, Annemieke M H ^a   Maier, Andrea B ^b   Stinissen, Piet ^c   Masson, Pierre ^d   Lories, Rik J ^e   De Keyser, Filip ^f  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c HASSELT UNIVERSITY   (Belgium)

^d DE DUVE INSTITUTE   (Belgium)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^f GHENT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADIPOCYTOKINE; C REACTIVE PROTEIN; CD28 ANTIGEN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; HEMOGLOBIN; INTERLEUKIN 1; INTERLEUKIN 6; LEPTIN; METHOTREXATE; PLACEBO; REACTIVE OXYGEN METABOLITE; TESTOSTERONE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR INHIBITOR;

ADAPTIVE IMMUNITY; AGE DISTRIBUTION; AGING; ANEMIA; ARTERIAL INSUFFICIENCY; CACHEXIA; CANCER RISK; CARDIOVASCULAR DISEASE; CD4 CD8 RATIO; COGNITIVE DEFECT; COMBINATION CHEMOTHERAPY; COMORBIDITY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DAS28; DENDRITIC CELL; DEPRESSION; DIABETES MELLITUS; DNA DAMAGE; DNA REPAIR; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EVOLUTION; EXERCISE; FRAIL ELDERLY; GASTROINTESTINAL DISEASE; GENETIC VARIABILITY; GENOTOXICITY; GERIATRIC DISORDER; GERIATRIC GIANT CONDITION; GERIATRICS; HAIR FOLLICLE; HEARING DISORDER; HUMAN; IMMUNE SYSTEM; IMMUNOPATHOGENESIS; INCONTINENCE; INFECTION; INFECTION RISK; INNATE IMMUNITY; LUNG DISEASE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE MIGRATION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE SUBPOPULATION; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR BIOLOGY; MONOCYTE; MONOTHERAPY; NATURAL KILLER CELL; ONSET AGE; OSTEOARTHRITIS; OSTEOPOROSIS; PEPTIC ULCER; PHENOTYPE; POLYPHARMACY; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION INJURY; REVIEW; RHEUMATOID ARTHRITIS; SENESCENCE; SENSORY DYSFUNCTION; SEX DIFFERENCE; SKIN CANCER; SYSTEMATIC REVIEW; TELOMERE HOMEOSTASIS; UNSPECIFIED SIDE EFFECT; VEIN INSUFFICIENCY; VISUAL DISORDER; WALKING DIFFICULTY;

AGING; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL FACTORS; DNA DAMAGE; HUMANS; IMMUNE SYSTEM; PHENOTYPE; TREATMENT OUTCOME;

EID: 84885316786     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2013.92     Document Type: Review

References (114)

1. Konrat, C. et al. Underrepresentation of elderly people in randomised controlled trials. The example of trials of 4 widely prescribed drugs. PLoS ONE 7, e33559 (2012).
2. Macieira-Coelho, A. Cell division and aging of the organism. Biogerontology 12, 503-515 (2011).
3. Sperka, T., Wang, J. & Rudolph, K. L. DNA damage checkpoints in stem cells, ageing and cancer. Nat. Rev. Mol. Cell. Biol. 13, 579-590 (2012).
4. Kirkwood, T. B. Evolution of ageing. Nature 270 301-304 (1977).
5. Kirkwood, T. L., Kapahi, P. & Shanley, D. P. Evolution, stress, and longevity. J. Anat. 197, 587-590 (2000).
6. Ljubuncic, P. & Reznick, A. Z. The evolutionary theories of aging revisited-a mini-review. Gerontology 55, 205-216 (2009).
7. Fulop, T. et al. Aging, frailty and age-related diseases. Biogerontology 11, 547-563 (2010).
8. Isaacs, B. The challenge of geriatric medicine (Oxford University Press, 1997).
9. Health Council of the Netherlands. Health care for the elderly with multimorbidity. Publication no. 2008/01 (Health Council of the Netherlands, 2008).
10. Lang, P. O., Michel, J. P. & Zekry, D. Frailty syndrome: a transitional state in a dynamic process. Gerontology 55, 539-549 (2009).
11. Fried, L. P. et al. Frailty in older adults: evidence for a phenotype. J. Gerontol. A Biol. Sci. Med. Sci. 56, M146-156 (2001). (Pubitemid 32187141)
12. Bandeen-Roche, K. et al. Phenotype of frailty: characterization in the women's health and aging studies. J. Gerontol. A Biol. Sci. Med. Sci. 61, 262-266 (2006).
13. Garonzik-Wang, J. M. et al. Frailty and delayed graft function in kidney transplant recipients. Arch. Surg. 147, 190-193 (2012).
14. Makary, M. A. et al. Frailty as a predictor of surgical outcomes in older patients. J. Am. Coll. Surg. 210, 901-908 (2010).
15. Yao, X. et al. Frailty is associated with impairment of vaccine-induced antibody response and increase in post-vaccination influenza infection in community-dwelling older adults. Vaccine 29, 5015-5021 (2011).
16. Abadir, P. M. et al. Identification and characterization of a functional mitochondrial angiotensin system. Proc. Natl Acad. Sci. USA 108, 14849-14854 (2011).
17. Leng, S. X., Yang, H. & Walston, J. D. Decreased cell proliferation and altered cytokine production in frail older adults. Aging Clin. Exp. Res. 16, 249-252 (2004). (Pubitemid 39232497)
18. Varadhan, R. et al. Higher levels and blunted diurnal variation of cortisol in frail older women. J. Gerontol. A Biol. Sci. Med. Sci. 63, 190-195 (2008). (Pubitemid 351738451)
19. Gameiro, C. & Romao, F. Changes in the immune system during menopause and aging. Front. Biosci. (Elite Ed.) 2, 1299-1303 (2010).
20. Gomez, C. R., Boehmer, E. D. & Kovacs, E. J. The aging innate immune system. Curr. Opin. Immunol. 17, 457-462 (2005). (Pubitemid 41207946)
21. Krabbe, K. S., Pedersen, M. & Bruunsgaard, H. Inflammatory mediators in the elderly. Exp. Gerontol. 39, 687-699 (2004). (Pubitemid 38586809)
22. Panda, A. et al. Human innate immunosenescence: causes and consequences for immunity in old age. Trends Immunol. 30, 325-333 (2009).
23. Shaw, A. C., Joshi, S., Greenwood, H., Panda, A. & Lord, J. M. Aging of the innate immune system. Curr. Opin. Immunol. 22, 507-513 (2010).
24. Goronzy, J. J., Shao, L. & Weyand, C. M. Immune aging and rheumatoid arthritis. Rheum. Dis. Clin. North Am. 36, 297-310 (2010).
25. Lindstrom, T. M. & Robinson, W. H. Rheumatoid arthritis: a role for immunosenescence J. Am. Geriatr. Soc. 58, 1565-1575 (2010).
26. Scullion, J. Tuberculosis and older people. Nurs. Older People 15, 23-27 (2003).
27. Frasca, D. & Blomberg, B. B. Aging affects human B cell responses. J. Clin. Immunol. 31, 430-435 (2011).
28. Lee, N., Shin, M. S. & Kang, I. T-cell biology in aging, with a focus on lung disease. J. Gerontol. A Biol. Sci. Med. Sci. 67, 254-263 (2012).
29. Hakim, F. T. et al. Age-dependent incidence, time course, and consequences of thymic renewal in adults. J. Clin. Invest. 115, 930-939 (2005). (Pubitemid 40489397)
30. Geginat, J., Lanzavecchia, A. & Sallusto, F. Proliferation and differentiation potential of human CD8+ memory T-cell subsets in response to antigen or homeostatic cytokines. Blood 101, 4260-4266 (2003). (Pubitemid 36857786)
31. Broux, B., Markovic-Plese, S., Stinissen, P. & Hellings, N. Pathogenic features of CD4+CD28-T cells in immune disorders. Trends Mol. Med. 18, 446-453 (2012).
32. Weng, N. P., Akbar, A. N. & Goronzy, J. CD28-T cells: their role in the age-associated decline of immune function. Trends Immunol. 30, 306-312 (2009).
33. Vallejo, A. N. et al. Molecular basis for the loss of CD28 expression in senescent T cells. J. Biol. Chem. 277, 46940-46949 (2002). (Pubitemid 36159198)
34. Valenzuela, H. F. & Effros, R. B. Divergent telomerase and CD28 expression patterns in human CD4 and CD8 T cells following repeated encounters with the same antigenic stimulus. Clin. Immunol. 105, 117-125 (2002). (Pubitemid 35471660)
35. Koch, S. et al. Cytomegalovirus infection: a driving force in human T cell immunosenescence. Ann. NY Acad. Sci. 1114, 23-35 (2007). (Pubitemid 350070409)
36. van Leeuwen, E. M. et al. Emergence of a CD4+CD28-granzyme B+, cytomegalovirus-specific T cell subset after recovery of primary cytomegalovirus infection. J. Immunol. 173, 1834-1841 (2004). (Pubitemid 38971617)
37. Schirmer, M., Vallejo, A. N., Weyand, C. M. & Goronzy, J. J. Resistance to apoptosis and elevated expression of Bcl-2 in clonally expanded CD4+CD28-T cells from rheumatoid arthritis patients. J. Immunol. 161, 1018-1025 (1998). (Pubitemid 28323570)
38. Vallejo, A. N., Schirmer, M., Weyand, C. M. & Goronzy, J. J. Clonality and longevity of CD4+CD28null T cells are associated with defects in apoptotic pathways. J. Immunol. 165, 6301-6307 (2000).
39. Vallejo, A. N. et al. Expansions of NK-like T cells with chronologic aging: novel lymphocyte effectors that compensate for functional deficits of conventional NK cells and T cells. Ageing Res. Rev. 10, 354-361 (2011).
40. Heyn, H. et al. Distinct DNA methylomes of newborns and centenarians. Proc. Natl Acad. Sci. USA 109, 10522-10527 (2012).
41. Liu, Y., Chen, Y. & Richardson, B. Decreased DNA methyltransferase levels contribute to abnormal gene expression in "senescent" CD4+CD28-T cells. Clin. Immunol. 132, 257-265 (2009).
42. Schmidt, D., Martens, P. B., Weyand, C. M. & Goronzy, J. J. The repertoire of CD4+ CD28-T cells in rheumatoid arthritis. Mol. Med. 2, 608-618 (1996). (Pubitemid 26353109)
43. Schmidt, D., Goronzy, J. J. & Weyand, C. M. CD4+CD7-CD28-T cells are expanded in rheumatoid arthritis and are characterized by autoreactivity. J. Clin. Invest. 97, 2027-2037 (1996). (Pubitemid 26143956)
44. Bristol-Myers Squibb. Abatacept summary of product characteristics [online], http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product- Information/human/000701/WC500048935.pdf
45. Kremer, J. M. et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N. Engl. J. Med. 349, 1907-1915 (2003). (Pubitemid 37409707)
46. Arai, Y., Takayama, M., Abe, Y. & Hirose, N. Adipokines and aging. J. Atheroscler. Thromb. 18, 545-550 (2011).
47. Conde, J. et al. Adipokines: novel players in rheumatic diseases. Discov. Med. 15, 73-83 (2013).
48. Gomez, R. et al. What's new in our understanding of the role of adipokines in rheumatic diseases Nat. Rev. Rheumatol. 7, 528-536 (2011).
49. Olama, S. M., Senna, M. K. & Elarman, M. Synovial/serum leptin ratio in rheumatoid arthritis: the association with activity and erosion. Rheumatol. Int. 32, 683-690 (2012).
50. Matarese, G., Procaccini, C., De Rosa, V., Horvath, T. L. & La Cava, A. Regulatory T cells in obesity: the leptin connection. Trends Mol. Med. 16, 247-256 (2010).
51. Giles, J. T., Allison, M., Bingham, C. O. 3rd, Scott, W. M. Jr & Bathon, J. M. Adiponectin is a mediator of the inverse association of adiposity with radiographic damage in rheumatoid arthritis. Arthritis Rheum. 61, 1248-1256 (2009).
52. Matthews, S. J. & Lancaster, J. W. Urinary tract infections in the elderly population. Am. J. Geriatr. Pharmacother. 9, 286-309 (2011).
53. Meyer, K. C. The role of immunity and inflammation in lung senescence and susceptibility to infection in the elderly. Semin. Respir. Crit. Care Med. 31, 561-574 (2010).
54. Mori, T. & Leung, C. C. Tuberculosis in the global aging population. Infect. Dis. Clin. North Am. 24, 751-768 (2010).
55. Jefferson, T. et al. Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review. Lancet 366, 1165-1174 (2005). (Pubitemid 41393594)
56. Kumar, R. & Burns, E. A. Age-related decline in immunity: implications for vaccine responsiveness. Expert. Rev. Vaccines 7, 467-479 (2008). (Pubitemid 351681640)
57. Lang, P. O., Govind, S., Mitchell, W. A., Siegrist, C. A. & Aspinall, R. Vaccine effectiveness in older individuals: what has been learned from the influenza-vaccine experience. Ageing Res. Rev. 10, 389-395 (2011).
58. Lang, P. O. et al. Effectiveness of influenza vaccine in aging and older adults: comprehensive analysis of the evidence. Clin. Interv. Aging 7, 55-64 (2012).
59. McElhaney, J. E. Influenza vaccine responses in older adults. Ageing Res. Rev. 10, 379-388 (2011).
60. Fujihashi, K. & Kiyono, H. Mucosal immunosenescence: new developments and vaccines to control infectious diseases. Trends Immunol. 30, 334-343 (2009).
61. Giuliano, S., Ohanna, M., Ballotti, R. & Bertolotto, C. Advances in melanoma senescence and potential clinical application. Pigment Cell Melanoma Res. 24, 295-308 (2011).
62. Lasithiotakis, K. G., Petrakis, I. E. & Garbe, C. Cutaneous melanoma in the elderly: epidemiology, prognosis and treatment. Melanoma Res. 20, 163-170 (2010).
63. Finkel, T., Serrano, M. & Blasco, M. A. The common biology of cancer and ageing. Nature 448, 767-774 (2007). (Pubitemid 47266334)
64. de Vlam, K. et al. Detection and identification of antinuclear autoantibodies in the serum of normal blood donors. Clin. Exp. Rheumatol. 11, 393-397 (1993). (Pubitemid 23287160)
65. Borchers, A. T. & Gershwin, M. E. Giant cell arteritis: a review of classification, pathophysiology, geoepidemiology and treatment. Autoimmun. Rev. 11, A544-A554 (2012).
66. Crowson, C. S. et al. The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis Rheum. 63, 633-639 (2011).
67. Fujii, H., Shao, L., Colmegna, I., Goronzy, J. J. & Weyand, C. M. Telomerase insufficiency in rheumatoid arthritis. Proc. Natl Acad. Sci. USA 106, 4360-4365 (2009).
68. Weyand, C. M., Fujii, H., Shao, L. & Goronzy, J. J. Rejuvenating the immune system in rheumatoid arthritis. Nat. Rev. Rheumatol. 5, 583-588 (2009).
69. Koetz, K. et al. T cell homeostasis in patients with rheumatoid arthritis. Proc. Natl Acad. Sci. USA 97, 9203-9208 (2000). (Pubitemid 30626698)
70. Goronzy, J. J. & Weyand, C. M. Immune aging and autoimmunity. Cell. Mol. Life Sci. 69, 1615-1623 (2012).
71. Colmegna, I. et al. Defective proliferative capacity and accelerated telomeric loss of hematopoietic progenitor cells in rheumatoid arthritis. Arthritis Rheum. 58, 990-1000 (2008). (Pubitemid 351564000)
72. Shao, L. et al. Deficiency of the DNA repair enzyme ATM in rheumatoid arthritis. J. Exp. Med. 206, 1435-1449 (2009).
73. Kohler, S. & Thiel, A. Life after the thymus: CD31+ and CD31-human naive CD4+ T-cell subsets. Blood 113, 769-774 (2009).
74. Lee, W. W., Yang, Z. Z., Li, G., Weyand, C. M. & Goronzy, J. J. Unchecked CD70 expression on T cells lowers threshold for T cell activation in rheumatoid arthritis. J. Immunol. 179, 2609-2615 (2007).
75. Singh, K., Colmegna, I., He, X., Weyand, C. M. & Goronzy, J. J. Synoviocyte stimulation by the LFA-1-intercellular adhesion molecule-2-Ezrin-Akt pathway in rheumatoid arthritis. J. Immunol. 180, 1971-1978 (2008).
76. Mavragani, C. P. & Moutsopoulos, H. M. Rheumatoid arthritis in the elderly. Exp. Gerontol. 34, 463-471 (1999). (Pubitemid 29293624)
77. Tutuncu, Z. & Kavanaugh, A. Rheumatic disease in the elderly: rheumatoid arthritis. Clin. Geriatr. Med. 21, 513-525 (2005). (Pubitemid 40720254)
78. van Schaardenburg, D. & Breedveld, F. C. Elderly-onset rheumatoid arthritis. Semin. Arthritis Rheum. 23, 367-378 (1994). (Pubitemid 24188343)
79. Villa-Blanco, J. I. & Calvo-Alen, J. Elderly onset rheumatoid arthritis: differential diagnosis and choice of first-line and subsequent therapy. Drugs Aging 26, 739-750 (2009).
80. Kermani, T. A. & Warrington, K. J. Polymyalgia rheumatica. Lancet 381, 63-72 (2013).
81. Chen, D. Y. et al. Proinflammatory cytokine profiles of patients with elderly-onset rheumatoid arthritis: a comparison with younger-onset disease. Gerontology 55, 250-258 (2009).
82. Glennas, A., Kvien, T. K., Andrup, O., Karstensen, B. & Munthe, E. Recent onset arthritis in the elderly: a 5 year longitudinal observational study. J. Rheumatol. 27, 101-108 (2000). (Pubitemid 30058636)
83. van der Heijde, D. M. et al. Older versus younger onset rheumatoid arthritis: results at onset and after 2 years of a prospective followup study of early rheumatoid arthritis. J. Rheumatol. 18, 1285-1289 (1991).
84. Gabriel, S. E. & Michaud, K. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res. Ther. 11, 229 (2009).
85. Maradit-Kremers, H. et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum. 52, 402-411 (2005). (Pubitemid 40220344)
86. Maradit-Kremers, H., Nicola, P. J., Crowson, C. S., Ballman, K. V. & Gabriel, S. E. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum. 52, 722-732 (2005). (Pubitemid 40365093)
87. Nicola, P. J. et al. The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years. Arthritis Rheum. 52, 412-420 (2005). (Pubitemid 40216304)
88. Madjid, M. & Willerson, J. T. Inflammatory markers in coronary heart disease. Br. Med. Bull. 100, 23-38 (2011).
89. Liao, K. P. & Solomon, D. H. Traditional cardiovascular risk factors, inflammation and cardiovascular risk in rheumatoid arthritis. Rheumatology (Oxford) 52, 45-52 (2013).
90. Smitten, A. L., Simon, T. A., Hochberg, M. C. & Suissa, S. A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res. Ther. 10, R45 (2008).
91. Baecklund, E. et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 54, 692-701 (2006).
92. Niccoli, T. & Partridge, L. Ageing as a risk factor for disease. Curr. Biol. 22, R741-R752 (2012).
93. Askling, J. & Bongartz, T. Malignancy and biologic therapy in rheumatoid arthritis. Curr. Opin. Rheumatol. 20, 334-339 (2008). (Pubitemid 351483325)
94. Doran, M. F., Crowson, C. S., Pond, G. R., O'Fallon, W. M. & Gabriel, S. E. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum. 46, 2287-2293 (2002).
95. De Keyser, F. Choice of biologic therapy for patients with rheumatoid arthritis: the infection perspective. Curr. Rheumatol. Rev. 7, 77-87 (2011).
96. Salliot, C., Dougados, M. & Gossec, L. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann. Rheum. Dis. 68, 25-32 (2009).
97. Crowson, C. S., Hoganson, D. D., Fitz-Gibbon, P. D. & Matteson, E. L. Development and validation of a risk score for serious infection in patients with rheumatoid arthritis. Arthritis Rheum. 64, 2847-2855 (2012).
98. Seitz, C. S., Berens, N., Brocker, E. B. & Trautmann, A. Leg ulceration in rheumatoid arthritis-an underreported multicausal complication with considerable morbidity: analysis of thirty-six patients and review of the literature. Dermatology 220, 268-273 (2010).
99. Summers, G. D., Deighton, C. M., Rennie, M. J. & Booth, A. H. Rheumatoid cachexia: a clinical perspective. Rheumatology (Oxford) 47, 1124-1131 (2008). (Pubitemid 352038214)
100. Munro, R. & Capell, H. Prevalence of low body mass in rheumatoid arthritis: association with the acute phase response. Ann. Rheum. Dis. 56, 326-329 (1997). (Pubitemid 27278522)
101. Chen, Y. M., Chen, L. K., Lan, J. L. & Chen, D. Y. Geriatric syndromes in elderly patients with rheumatoid arthritis. Rheumatology (Oxford) 48, 1261-1264 (2009).
102. Ziade, N., Jougla, E. & Coste, J. Population-level influence of rheumatoid arthritis on mortality and recent trends: a multiple cause-of-death analysis in France, 1970-2002. J. Rheumatol. 35, 1950-1957 (2008).
103. Fraenkel, L., Rabidou, N. & Dhar, R. Are rheumatologists' treatment decisions influenced by patients' age Rheumatology (Oxford) 45, 1555-1557 (2006). (Pubitemid 44817064)
104. Schmajuk, G. et al. Treatment of older adult patients diagnosed with rheumatoid arthritis: improved but not optimal. Arthritis Rheum. 57, 928-934 (2007). (Pubitemid 47237318)
105. Radovits, B. J., Fransen, J., Eijsbouts, A., van Riel, P. L. & Laan, R. F. Missed opportunities in the treatment of elderly patients with rheumatoid arthritis. Rheumatology (Oxford) 48, 906-910 (2009).
106. Radovits, B. J. et al. Influence of age on the outcome of antitumour necrosis factor alpha therapy in rheumatoid arthritis. Ann. Rheum. Dis. 68, 1470-1473 (2009).
107. Bathon, J. M. et al. Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis. J. Rheumatol. 33, 234-243 (2006). (Pubitemid 43209297)
108. Fleischmann, R. M. et al. Response to etanercept (Enbrel) in elderly patients with rheumatoid arthritis: a retrospective analysis of clinical trial results. J. Rheumatol. 30, 691-696 (2003). (Pubitemid 36402759)
109. Lurati, A., Marrazza, M., Angela, K. & Scarpellini, M. Safety of etanercept in elderly subjects with rheumatoid arthritis. Biologics 4, 1-4 (2010).
110. Genevay, S. et al. Tolerance and effectiveness of anti-tumor necrosis factor alpha therapies in elderly patients with rheumatoid arthritis: a population-based cohort study. Arthritis Rheum. 57, 679-685 (2007). (Pubitemid 46764060)
111. Galloway, J. B. et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford) 50, 124-131 (2011).
112. Schneeweiss, S. et al. Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthritis Rheum. 56, 1754-1764 (2007). (Pubitemid 47110375)
113. Dotan, E., Browner, I., Hurria, A. & Denlinger, C. Challenges in the management of older patients with colon cancer. J. Natl Compr. Canc. Netw. 10, 213-224 (2012).
114. Pallis, A. G. & Scarci, M. Are we treating enough elderly patients with early stage non-small cell lung cancer Lung Cancer 74, 149-154 (2011).